South Miami Hospital Harry Kapp Symposium Evaluation

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice

	5	4	3	2	1	NA
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - NA
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - NA

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice

	5	4	3	2	1	NA
Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD.	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - 5	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - 4	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - 3	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - 2	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - 1	Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD. - NA
Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future.	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - 5	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - 4	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - 3	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - 2	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - 1	Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future. - NA
Analyze the expanding use of e-cigarettes among adolescents.	Analyze the expanding use of e-cigarettes among adolescents. - 5	Analyze the expanding use of e-cigarettes among adolescents. - 4	Analyze the expanding use of e-cigarettes among adolescents. - 3	Analyze the expanding use of e-cigarettes among adolescents. - 2	Analyze the expanding use of e-cigarettes among adolescents. - 1	Analyze the expanding use of e-cigarettes among adolescents. - NA
Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response.	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - 5	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - 4	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - 3	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - 2	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - 1	Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response. - NA
Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF).	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - 5	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - 4	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - 3	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - 2	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - 1	Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF). - NA
Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment.	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - 5	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - 4	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - 3	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - 2	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - 1	Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment. - NA
Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes.	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - 5	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - 4	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - 3	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - 2	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - 1	Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes. - NA
Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection.	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - 5	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - 4	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - 3	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - 2	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - 1	Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection. - NA
Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM.	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - 5	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - 4	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - 3	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - 2	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - 1	Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM. - NA

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, NA=Not Applicable Speakers are listed according to the lecture schedule.

	5	4	3	2	1	NA
Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D.	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - 5	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - 4	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - 3	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - 2	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - 1	Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers - Ilona Jaspers, Ph.D. - NA
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D.	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - 5	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - 4	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - 3	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - 2	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - 1	New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? - Ronald C. Balkissoon, M.D. - NA
Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D.	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - 5	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - 4	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - 3	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - 2	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - 1	Interstitial Pulmonary Fibrosis - Mark Rumbak, M.D. - NA
State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D.	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - 5	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - 4	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - 3	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - 2	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - 1	State of the Art: Treating Nontuberculous Mycobacterial Infections - Jorge Murillo, M.D. - NA
Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D.	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - 5	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - 4	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - 3	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - 2	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - 1	Acute Respiratory Distress Syndrome - Juan Francisco Rodriguez-Moran, M.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

No

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

No

If you checked "No,” please tell us why: *

Would you recommend this symposium to a colleague? *

If you checked "No,” please explain why you would not recommend this course: *

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

You are here

South Miami Hospital Harry Kapp Symposium Evaluation